Exagen Inc. (XGN) Revenue History
Annual and quarterly revenue from 2013 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
XGN Revenue Growth
Revenue Breakdown (FY 2025)
XGN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
XGN Revenue Analysis (2013–2025)
As of May 8, 2026, Exagen Inc. (XGN) generated trailing twelve-month (TTM) revenue of $66.6 million, reflecting exceptional growth of +21.8% year-over-year. The most recent quarter (Q4 2025) recorded $16.6 million in revenue, down 3.6% sequentially.
Looking at the longer-term picture, XGN's 5-year compound annual growth rate (CAGR) stands at +9.7%, indicating steady revenue expansion. The company achieved its highest annual revenue of $66.6 million in 2025, representing a new all-time high.
Revenue diversification analysis shows XGN's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including CDNA (+19.2% YoY), NTRA (+35.9% YoY), and VCYT (+16.9% YoY), XGN has underperformed the peer group in terms of revenue growth. Compare XGN vs CDNA →
XGN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| XGNCurrent | $67M | +21.8% | +9.7% | -21.1% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 VCYT | $517M | +16.9% | +34.5% | 14.3% | |
 CSTL | $344M | -2.1% | +40.6% | -12.4% | |
 MYGN | $825M | -0.3% | +8.2% | -8.2% |
XGN Historical Revenue Data (2013–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $66.6M | +19.7% | $38.8M | 58.3% | $-14,070,000 | -21.1% |
| 2024 | $55.6M | +5.9% | $33.1M | 59.5% | $-13,636,000 | -24.5% |
| 2023 | $52.5M | +15.3% | $29.5M | 56.1% | $-22,837,000 | -43.5% |
| 2022 | $45.6M | -5.7% | $21.3M | 46.9% | $-46,051,000 | -101.1% |
| 2021 | $48.3M | +15.1% | $27.7M | 57.4% | $-24,067,000 | -49.8% |
| 2020 | $42.0M | +3.9% | $25.4M | 60.6% | $-15,185,000 | -36.2% |
| 2019 | $40.4M | +24.5% | $21.6M | 53.4% | $-9,299,000 | -23.0% |
| 2018 | $32.4M | +21.0% | $17.1M | 52.6% | $-4,880,000 | -15.0% |
| 2017 | $26.8M | +49.4% | $12.7M | 47.3% | $-7,836,000 | -29.2% |
| 2015 | $17.9M | +53.9% | $8.4M | 46.9% | $-10,388,000 | -57.9% |
See XGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXGN — Frequently Asked Questions
Quick answers to the most common questions about buying XGN stock.
Is XGN's revenue growth accelerating or slowing?
XGN revenue is accelerating at +21.8% year-over-year, exceeding the 5-year CAGR of +9.7%. TTM revenue reached $67M. Growth momentum has increased versus prior periods.
What is XGN's long-term revenue growth rate?
Exagen Inc.'s 5-year revenue CAGR of +9.7% reflects the sustained expansion pattern. Current YoY growth of +21.8% is above this long-term average.
How is XGN's revenue distributed by segment?
XGN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2025 are available for download. Segment mix reveals concentration and diversification trends.